Observing blood transfusion effects in bladder cancer surgery
Nordic Cystectomy Study III - Prospective Validation of Transfusions as a Poor Prognostic Factor After Radical Cystectomy for Bladder Cancer
This study looks at how blood transfusions during bladder cancer surgery affect recovery and outcomes for patients with muscle invasive bladder cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Turku University Hospital Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Turku, Southwest Finland) |
| Trial ID | NCT04537221 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with muscle invasive bladder cancer who are undergoing radical cystectomy, with or without neoadjuvant chemotherapy. It aims to assess the impact of blood transfusions on patient outcomes and recovery following surgery. The study will collect data on patient demographics, treatment plans, and postoperative results to better understand the risks and benefits associated with blood transfusions in this context. By analyzing these factors, the study seeks to improve individual risk assessments and treatment planning for bladder cancer patients.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with histologically confirmed muscle invasive bladder cancer scheduled for radical cystectomy.
Not a fit: Patients undergoing radical cystectomy for reasons other than bladder cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment protocols and improve recovery outcomes for bladder cancer patients undergoing surgery.
How similar studies have performed: While there have been studies on blood transfusions in surgical settings, this specific observational approach in bladder cancer treatment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed urinary BC planned to be treated with RC with or without neoadjuvant chemotherapy. * Histologically confirmed urinary BC planned to be treated with palliative cystectomy * Signed informed consent * Patient age \>18 years Exclusion Criteria: * RC for other reasons than BC * Other forms of surgical treatment of BC than RC (e.g. bladder resection). * Patient unwillingness to participate in the study for any reason (i.e. lack of signed consent).
Where this trial is running
Turku, Southwest Finland
- University Hospital of Turku, Hospital Distric of Southwest Finland — Turku, Southwest Finland, Finland (Recruiting)
Study contacts
- Principal investigator: Peter Boström, MD, PhD — Turku University Hospital
- Study coordinator: Otto Ettala, MD, PhD
- Email: otto.ettala@tyks.fi
- Phone: 23130280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.